Genistein attenuates advanced glycation end product-induced expression of fibronectin and connective tissue growth factor

American Journal of Nephrology

Volumn 36, Issue 1, 2012, Pages 34-40

  Tong, Mengli ^a   Wang, Yuhui ^a   Wang, Yongjun ^a   Chen, Hongyu ^a   Wang, Chengda ^a   Yang, Luchun ^a   Axelsson, Jonas ^b   Lindholm, Bengt ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Advanced glycation end products; Genistein; Peritoneal mesothelial cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GENISTEIN; MESSENGER RNA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PERITONEAL FIBROSIS; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANIMALS; CATTLE; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FIBRONECTINS; GENE EXPRESSION REGULATION; GENISTEIN; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PERITONEUM; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; TIME FACTORS;

EID: 84862181014     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000339168     Document Type: Article

References (52)

1. Plum J, et al: Peritoneal sclerosis in perito-neal dialysis patients related to dialysis set-tings and peritoneal transport properties. Kidney Int Suppl 2001; 78:S42-S47. (Pubitemid 32144068)
2. Dobbie JW: Pathogenesis of peritoneal fi-brosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
3. Linden T, et al: 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kid-ney Int 2002; 62: 697-703. (Pubitemid 34779784)
4. Miyata T, Kurokawa K, Van Ypersele DSC: Advanced glycation and lipoxidation end products: role of reactive carbonyl com-pounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11: 1744-1752.
5. Witowski J, et al: Effect of glucose degrada-tion products on human peritoneal mesothe-lial cell function. J Am Soc Nephrol 2000; 11: 729-739. (Pubitemid 30171882)
6. Witowski J, et al: Prolonged exposure to glu-cose degradation products impairs viability and function of human peritoneal mesothe- lial cells. J Am Soc Nephrol 2001; 12:2434-2441. (Pubitemid 33021121)
7. Arnott JA, et al: Connective tissue growth factor (CTGF/CCN2) is a downstream me-diator for TGF-beta1-induced extracellular matrix production in osteoblasts. J Cell Physiol 2007; 210:843-852. (Pubitemid 46185053)
8. Ihn H: Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14:681-685. (Pubitemid 35191556)
9. Adlercreutz CH, et al: Soybean phytoestro-gen intake and cancer risk. J Nutr 1995; 125(3 suppl):757S-770S.
10. Mukhopadhyay D, et al: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995; 375: 577-581.
11. Tatsuta M, et al: Attenuation by genistein of sodium-chloride-enhanced gastric carcino-genesis induced by N-methyl-N'-nitro-N-ni-trosoguanidine in Wistar rats. Int J Cancer 1999; 80: 396-399. (Pubitemid 29019626)
12. Huang J, et al: Genistein inhibits protein his-tidine kinase. J Biol Chem 1992; 267: 15511-15515.
13. Kim YS, et al: Genistein inhibits aldose re-ductase activity and high glucose-induced TGF-beta2 expression in human lens epi-thelial cells. Eur J Pharmacol 2008; 594: 18-25.
14. Yuan WJ, Jia FY, Meng JZ: Effects of genis-tein on secretion of extracellular matrix components and transforming growth fac-tor beta in high-glucose-cultured rat me-sangial cells. J Artif Organs 2009; 12:242-246.
15. Cao C, et al: Effects of genistein on expres-sion of TGF-beta1 and intracellular free Ca2+ concentration in fibroblasts derived from human hypertrophic scar. Zhonghua Zheng Xing Wai Ke Za Zhi 2008; 24:335-338.
16. Wang Q, et al: Effects of tyrosine protein ki-nase inhibitor genistein on the cell cycles of activated hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 53.
17. Shi H Y, Xu JW, Ren XX: Effect of genistein on hepatic stellate cell proliferation and lipid peroxidation in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:2066-2068.
18. Wagner Z, et al: N(epsilon)-(carboxymethyl) lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis 2001; 38:785-791.
19. Schalkwijk CG, et al: Induction of 1,2-dicar-bonyl compounds, intermediates in the for-mation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999; 19: 325-333. (Pubitemid 30011695)
20. Holmes CJ, Faict D: Peritoneal dialysis solu-tion biocompatibility: definitions and evalu-ation strategies. Kidney Int Suppl 2003:S50-S56. (Pubitemid 37452814)
21. Prakash J, et al: Non-infectious complica-tions of continuous ambulatory peritoneal dialysis and their impact on technique sur-vival. Indian J Nephrol 2011; 21:112-115.
22. Sampimon DE, et al: The time course of peri-toneal transport parameters in peritoneal di-alysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Trans-plant 2011; 26: 291-298.
23. Williams JD, et al: Morphologic changes in the peritoneal membrane of patients with re-nal disease. J Am Soc Nephrol 2002; 13: 470-479. (Pubitemid 34106290)
24. Boulanger E, et al: The triggering of human peritoneal mesothelial cell apoptosis and on-cosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004; 19: 2208-2216. (Pubitemid 39214112)
25. Lai KN, et al: Differential expression of re-ceptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Im-munol 2004; 138: 466-475. (Pubitemid 39573627)
26. Boulanger E, et al: AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 ex-pression. Kidney Int 2002; 61:148-156. (Pubitemid 34075141)
27. Schwenger V, et al: Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced gly-cation end-products. J Am Soc Nephrol 2006; 17: 199-207.
28. Ball DK, et al: Characterization of 16-to 20-kilodalton (kDa) connective tissue growth factors (CTGFs) and demonstration of proteolytic activity for 38-kDa CTGF in pig uterine luminal flushings. Biol Reprod 1998; 59: 828-835. (Pubitemid 28463334)
29. Liu DG, Wang TM: Role of connective tissue growth factor in experimental radiation ne-phropathy in rats. Chin Med J (Engl) 2008; 121: 1925-1931.
30. Burns WC, et al: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epi-thelial-to-mesenchymal transition: implica-tions for diabetic renal disease. J Am Soc Nephrol 2006; 17: 2484-2494. (Pubitemid 44300964)
31. Abdel-Wahab N, et al: Connective tissue growth factor and regulation of the mesan-gial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 2002; 13: 2437-2445.
32. Liu BC, et al: Role of connective tissue growth factor (CTGF) module 4 in regulat-ing epithelial mesenchymal transition (EMT) in HK-2 cells. Clin Chim Acta 2006; 373: 144-150.
33. Zarrinkalam KH, et al: Connective tissue growth factor and its regulation in the peri-toneal cavity of peritoneal dialysis patients. Kidney Int 2003; 64:331-338. (Pubitemid 36714188)
34. Qi W, et al: TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am J Physiol Renal Physiol 2006; 290:F703-F709. (Pubitemid 43724973)
35. Colwell AS, et al: Hypertrophic scar fi-broblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast Recon-str Surg 2005; 116:1387-1390; discussion 1391-1392. (Pubitemid 41456511)
36. Okada H, et al: Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005; 16: 133-143. (Pubitemid 43073165)
37. Qi W, et al: Integrated actions of transform-ing growth factor-beta1 and connective tis-sue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005; 288:F800-F809. (Pubitemid 40381749)
38. Shyong EQ, et al: Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. Carcino-genesis 2002; 23: 317-321. (Pubitemid 34224009)
39. Qi W, et al: Genistein inhibits proliferation of colon cancer cells by attenuating a nega-tive effect of epidermal growth factor on tu-mor suppressor FOXO3 activity. BMC Can-cer 2011; 11:219.
40. Kim HA, Jeong KS, Kim YK: Soy extract is more potent than genistein on tumor growth inhibition. Anticancer Res 2008; 28:2837-2841.
41. Tominaga Y, et al: Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe. Cell Death Differ 2007; 14: 472-479.
42. Ding W, Liu Y: Genistein attenuates genio-glossus muscle fatigue under chronic inter-mittent hypoxia by down-regulation of oxi-dative stress level and up-regulation of anti-oxidant enzyme activity through ERK1/2 signaling pathway. Oral Dis 2011; 17:677-684.
43. Park CE, et al: The antioxidant effects of ge-nistein are associated with AMP-activated protein kinase activation and PTEN induc-tion in prostate cancer cells. J Med Food 2010; 13: 815-820.
44. Neelakandan C, et al: In vitro evaluation of antioxidant and anti-inflammatory proper-ties of genistein-modified hemodialysis membranes. Biomacromolecules 2011; 12: 2447-2455.
45. Caruso MG, et al: Early induction of LDL re-ceptor gene expression by genistein in DLD-1 colon cancer cell line. Fitoterapia 2008; 79: 524-528.
46. Cooke PS, Selvaraj V, Yellayi S: Genistein es-trogen receptors, and the acquired immune response. J Nutr 2006; 136: 704-708. (Pubitemid 43363758)
47. Wang J, et al: Genistein inhibits the develop-ment of atherosclerosis via inhibiting NF-kappaB and VCAM-1 expression in LDLR knockout mice. Can J Physiol Pharmacol 2008; 86:777-784.
48. McCarty MF, Barroso-Aranda J, Contreras F: Genistein and phycocyanobilin may pre-vent hepatic fibrosis by suppressing prolif-eration and activation of hepatic stellate cells. Med Hypotheses 2009; 72:330-332.
49. Salas AL, et al: Genistein decreases liver fi-brosis and cholestasis induced by prolonged biliary obstruction in the rat. Ann Hepatol 2007; 6:41-47. (Pubitemid 46407488)
50. Salas AL, et al: Genistein modifies liver fi-brosis and improves liver function by induc-ing uPA expression and proteolytic activity in CCl4-treated rats. Pharmacology 2008; 81: 41-49.
51. Sung MJ, et al: Genistein protects the kidney from cisplatin-induced injury. Kidney Int 2008; 74: 1538-1547.
52. Lee SK, et al: High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kid-ney Int 2001; 60:55-64.